Boston Scientific's Synergy bioabsorbable polymer drug-eluting stent is on track for FDA approval after the successful Evolve II clinical trial, experts said, citing data released yesterday at the American Heart Association meeting in Chicago.
With a brand-new $156 million Gates Foundation grant in hand, the PATH Malaria Vaccine Initiative has signed on Switzerland-based Mymetics to develop and produce virosome-based vaccine formulations for a malaria transmission-blocking vaccine candidate.
As the diagnostics industry explores innovative ways to monitor and contain bacterial infections, Illumina is joining forces with French diagnostic outfit bioMérieux to develop a next-generation sequencing system that can identify infectious bacteria in service labs and hospitals.
Investors shouldn't expect any major change in the R&D game plan set up by the recently departed CEO Chris Viehbacher. Sanofi says it will stay committed to Viehbacher's "open innovation" strategy, relying heavily on partners like Regeneron to produce next-gen drugs needed to keep up its revenue.
Federal regulators are proposing a rule that would require makers of drugs and medical devices to publicize the results of thousands of clinical trials, regardless of whether they succeed, part of a global move toward transparency in R&D.
Amid growing efforts to quell the deadly Ebola outbreak, diagnostic giant Illumina is teaming up with U.S. government officials and Broad Institute researchers to help scientists in West Africa track the virus in real time and develop new tools to prevent its spread.
Novartis hasn't been shy about digital. The Swiss drugmaker has rolled out app after app to help patients track their symptoms and stay on their drugs. But CEO Joe Jimenez says the company is about to do a lot more than that.
As hospitals scramble to reduce readmissions, or face punishment under the Affordable Care Act's Hospital Readmissions Reduction Program, they are increasingly turning to efficiency-promoting devices like St. Jude Medical's CardioMEMS HF System for monitoring heart failure patients.
Cynapsus Therapeutics touted the results of its Phase 2 clinical trial of its sublingual thin-film-strip formulation of apomorphine for the management of OFF motor symptoms of Parkinson's disease.
Researchers at the University of California in San Diego have developed a way to disguise the genetic material itself so that it can enter cells and shut down genetic diseases at the core.